Items Tagged ‘Multiple Myeloma’

December 13th, 2017

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma

By

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are not eligible to undergo a stem cell transplant. These results were presented as a late-breaking abstract at the 2017 annual meeting […]

View full entry

Tags: bortezomib, daratumumab, Darzalex, melphalan, Multiple Myeloma, News, Precision Cancer Medicine, prednisone, velcade, VMP


November 20th, 2017

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor

By

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you […]

View full entry

Tags: Multiple Myeloma, News


September 25th, 2017

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

By

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold over safety concerns while further […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, Multiple Myeloma, News, PD-1, PD-L1


August 16th, 2017

Bone Marrow Transplant Program Celebrates Its First Year

By msequeira msequeira

The Bone Marrow Transplant Program at the UNM Comprehensive Cancer Center has been treating people with blood disorders for a little more than a year. The first people to be treated are now celebrating one year since their treatment ended. New Mexicans no longer need to leave home to get access to these kinds of […]

View full entry

Tags: blood cancer, Blood transfusions, Lymphoma, Multiple Myeloma


July 13th, 2017

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift

By

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated with Revlimid alone were recently presented in an oral session today during the 22nd Congress of the European Hematology Association in Madrid, Spain.  Combination […]

View full entry

Tags: cancer precision medicine, ELOQUENT-2 clinical trial, elotuzumab, Empliciti, lenalidomide, Multiple Myeloma, News, revlimid


April 25th, 2017

Revlimid Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults

By

Results from a pivotal clinical trial have supported the use of Revlimid (lenalidomide) as maintenance therapy for patients multiple myeloma.  A new analysis from the trial just published in the Journal, Blood raises concerns about the safety of Revlimd maintenance reporting an increased risk of developing secondary cancer. Doctors from the Institute of Cancer Research […]

View full entry

Tags: maintenance therapy, Multiple Myeloma, News, revlimid


March 28th, 2017

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

By

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication makes Revlimid® the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.1 Autologous stem cell transplant after […]

View full entry

Tags: maintenance, Multiple Myeloma, News, revlimid, secondary cancer, secondary malignancy


March 22nd, 2017

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma

By

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma.  Patients with relapsed […]

View full entry

Tags: kyprolis, Multiple Myeloma, News, proteosome inhibitors


December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

By

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or […]

View full entry

Tags: Blood transfusions, Hodgkin's Lymphoma, Leukemia, long-term, Multiple Myeloma, Myeloproliferative Neoplasms MPN, News, Non-Hodgkin's Lymphoma, short-term, storage


November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

By

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients with MM. The clinical trial […]

View full entry

Tags: ASCT, bortezomib, clinical trial, cyclophosphamide, dexamethasone, HOVON, Multiple Myeloma, News, Stem Cell Transplant, velcade


July 7th, 2016

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

By

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that […]

View full entry

Tags: blood cancer, daratumumab, Darxalex, IMid, Multiple Myeloma, News, PI, proteasome inhibitor, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


April 21st, 2016

Aplidin® Improves Progression-Free Survival in Multiple Myeloma

By

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with multiple myeloma that has progressed following prior therapies. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells […]

View full entry

Tags: ADMYRE, Aplidin, ascidian Aplidium albicans, blood cancer, Multiple Myeloma, News, plasma cells, Plitidepsin, Recurrent Multiple Myeloma


March 30th, 2016

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

By

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic VOD. Hepatic VOD is a rare, but life-threatening complication that can occur following chemotherapy and a stem cell transplant (SCT) […]

View full entry

Tags: Chemotherapy, chemotherpay, hepatic VOC, Hodgkin's Lymphoma, HSCT, Leukemia, Lymphoma, Multiple Myeloma, News, Non-Hodgkin's Lymphoma, Stem Cell Transplant


January 26th, 2016

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma

By

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important […]

View full entry

Tags: carfilzomib, dexamethasone, ENDEAVOR, fda, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma